LONDON (ShareCast) - (Sharecast News) - Clinical-stage drug development company Evgen Pharma announced its support for a new research collaboration between King's College London and the British Heart Foundation on Monday, investigating how Evgen's SFX-01 could provide neurovascular protection in ischaemic stroke through Nrf2-regulated redox signalling.
The AIM-traded firm said the collaboration was being funded principally by the British Heart Foundation as a PhD studentship.

Evgen would supply SFX-01 to the project, and had the right to negotiate a licence over any resultant intellectual property, on fair and reasonable preferential terms.

If successful, the research would provide further insight into how SFX-01 mediated upregulation of Nrf2 in the blood-brain barrier endothelium, thereby enhancing neurovascular protection.

It said the work would build on the existing collaboration between Evgen and King's, which had demonstrated vascular protection in murine models of ischaemic stroke.

"welcome the opportunity to continue working with Professor Mann in developing the opportunities for SFX-01 in neurology," said chief executive officer Steve Franklin.

"Meanwhile, we look forward to our Phase IIb clinical data from SFX-01 in subarachnoid stroke which we will announce later this year."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE